STTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Shattuck Labs (STTK) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong positive catalysts, bullish technical indicators, and favorable analyst ratings, making it a promising long-term investment opportunity.
The stock exhibits bullish technical indicators. The MACD is positively expanding, RSI is neutral at 70.884, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The current pre-market price of $7.35 is above the pivot level of $6.893, with resistance levels at $7.512 and $7.894.
Multiple analysts have raised price targets recently, with targets ranging from $7 to $
Analysts highlight the differentiation and potential of the company's lead asset, SL-325, in treating inflammatory bowel disease.
Upcoming Phase 1 data for SL-325 in Q2 2026 is expected to act as a significant catalyst.
The stock has a 70% chance of gaining 4.22% in the next week and 11.85% in the next month.
Financial performance in the latest quarter (2025/Q
shows a net income decline of -32.58% YoY and a significant EPS drop of -67.57% YoY.
No recent news or congress trading data to further support sentiment.
In 2025/Q4, the company reported no revenue growth (0% YoY), a net income loss of -$12.59M (-32.58% YoY), and a significant EPS drop to -0.12 (-67.57% YoY). However, gross margin remains at 100%.
Analysts are bullish overall. Citi raised its price target to $7 and added a 90-day upside catalyst watch. Wedbush increased its target to $8 with an Outperform rating. Needham initiated a Buy rating with a $14 target, citing a highly favorable risk/reward profile. Piper Sandler initiated coverage with an Overweight rating and a $15 target, highlighting the differentiated approach of SL-325.
